Cited by 339Migraine and Headache StudiesHealth Systems, Economic Evaluations, Quality of LifeMusculoskeletal pain and rehabilitation

Cost of healthcare for patients with migraine in five European countries: results from the International Burden of Migraine Study (IBMS)

Open access
Bloudek, L. M., Stokes, M., Buse, D. C., Wilcox, T. K., Lipton, R. B., Goadsby, P. J., Varon, S. F., Blumenfeld, A. M. +5 more·2012·The Journal of Headache and Pain

Abstract

Migraine is a disabling neurological disease that affects 14.7 % of Europeans. Studies evaluating the economic impact of migraine are complex to conduct adequately and with time become outdated as healthcare systems evolve. This study sought to quantify and compare direct medical costs of chronic migraine (CM) and episodic migraine (EM) in five European countries. Cross-sectional data collected via a web-based survey were screened for migraine and classified as CM (≥15 headache days/month) or EM (<15 headache days/month), and included sociodemographics, resource use data and medication use. Unit cost data, gathered using publicly available sources, were analyzed for each type of service, stratified by migraine status. Univariate and multivariate log-normal regression models were used to examine the relationship between various factors and their impact on total healthcare costs. This economic analysis included data from respondents with migraine in the UK, France, Germany, Italy, and Spain. CM participants had higher level of disability and more prevalent psychiatric disorders compared to EM. CM participants had more provider visits, emergency department/hospital visits, and diagnostic tests; the medical costs were three times higher for CM than EM. Per patient annual costs were highest in the UK and Spain and lower in France and Germany. CM was associated with higher medical resource use and total costs compared to EM in all study countries, suggesting that treatments that reduce headache frequency could decrease the clinical and economic burden of migraine in Europe. Comparing patterns of care and outcomes among countries may facilitate the development of more cost-effective care, and bring greater recognition to patients affected by migraine.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1007/s10194-012-0460-7

Cites

38 of 38 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • No detailed assessment of the current treatment pathway, impact on work productivity, or burden associated with premonitory and postdromal phases of migraine is available in individuals experiencing ≥4 monthly migraine days who have had previous prophylactic treatments that failed and continue to experience frequent migraines.

    “Specifically, no detailed assessment of the current treatment pathway, impact on work productivity, or burden associated with premonitory and postdromal phases of migraine is available in individuals experiencing ≥4 MMDs who have had previous prophylactic treatments that failed and continue to experience frequent migraines.”
  • Current understanding of migraine burden among individuals with the highest unmet needs, specifically those experiencing ≥4 monthly migraine days and prior prophylaxis failure, is limited.

    “However, the current understanding of migraine burden among individuals with the highest unmet needs, specifically those experiencing ≥4 monthly migraine days (MMDs) and prior prophylaxis failure, is limited.”
  • The findings are consistent with the results of the IBMS study, which found that for each of the five European countries studied, chronic migraine was associated with additional healthcare costs attributable to increased use of medical services and associated cost.

    “These findings are consistent with the results of the IBMS study, which found that for each of the five European countries studied, chronic migraine (per ICHD-2 criteria, persons with ≥15 MMDs) was associated with additional healthcare costs attributable to an increased use of medical services and associated cost [6].”

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Bloudek, L. M., Stokes, M., Buse, D. C., Wilcox, T. K., Lipton, R. B., Goadsby, P. J., Varon, S. F., Blumenfeld, A. M., Katsarava, Z., Pascual, J., Lanteri-Minet, M., Cortelli, P., & Martelletti, P.
Affiliations
  • Allergan (United States) (US)
  • Albert Einstein College of Medicine (US)
  • University of California, San Francisco (US)
  • Essen University Hospital (DE)
  • Hospital Universitario Central de Asturias (ES)
  • University of Bologna (IT)
  • Azienda Ospedaliera Sant'Andrea (IT)
Corresponding author
Bloudek, L. M.
Venue
The Journal of Headache and Pain
Published
2012-05-29
Volume
13
Issue
5
Pages
361-378
ISSN
  • 1129-2369 (ISSN-L)
  • 1129-2377
OpenAlex
W2094473459
Cited by
339
References
38
Citations by year
2026: 6 · 2025: 16 · 2024: 26 · 2023: 19 · 2022: 18 · 2021: 38 · 2020: 36 · 2019: 34 · 2018: 25 · 2017: 25 · 2016: 17 · 2015: 17 · 2014: 30 · 2013: 25 · 2012: 6
FWCI
17.76
Type
journal article
Language
en
Open access
Locations
  • The Journal of Headache and Pain (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • Research Portal (King's College London) (publishedVersion, other-oa)
  • Archivio istituzionale della ricerca (Alma Mater Studiorum Università di Bologna) (submittedVersion, cc-by)
  • eScholarship (California Digital Library) (submittedVersion)
  • IRIS Research product catalog (Sapienza University of Rome) (submittedVersion)
Funders
  • University of Washington
  • Allergan
Topics
  • Health Sciences › Medicine › Psychiatry and Mental health › Migraine and Headache Studies
  • Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Health Systems, Economic Evaluations, Quality of Life
  • Health Sciences › Medicine › Pharmacology › Musculoskeletal pain and rehabilitation
Keywords
migraine, chronic migraine, episodic migraine, health care costs, direct medical costs, health care utilization, disability, psychiatric comorbidity, emergency department visits, hospital visits, diagnostic testing, medication use, cross-national comparison
MeSH terms
Cross-Sectional Studies, Europe, Female, Persons with Disabilities, Health Surveys, Humans, Male, Migraine Disorders, Health Care Costs

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review